Treatment of sporadic hemiplegic migraine with calcium-channel blocker verapamil.

Abstract

Gene mutations within the P/Q type neuronal calcium channel in familial hemiplegic migraine (FHM) suggest a therapeutic role for calcium-channel blockade. The authors have previously reported abortive therapy of FHM with IV verapamil. Here the authors describe four cases of sporadic hemiplegic migraine (SHM) responsive to verapamil, administered either orally or IV. The findings indicate that verapamil is effective therapy for both SHM and FHM.

• Authors: Wengui Yu, Steven H Horowitz
• Journal: Neurology (Neurology) Vol. 60 Issue 1 Pg. 120-1 (Jan 14 2003) ISSN: 1526-632X [Electronic] United States
• PMID: 12525732 (Publication Type: Case Reports, Journal Article)

Chemical References

• Calcium Channel Blockers
• Verapamil
• Acetazolamide

Topics

• Acetazolamide (adverse effects, therapeutic use)
• Adult
• Calcium Channel Blockers (adverse effects, therapeutic use)
• Female
• Follow-Up Studies
• Hemiplegia (complications)
• Humans
• Hypotension, Orthostatic (chemically induced)
• Migraine with Aura (complications, drug therapy)
• Treatment Outcome
• Verapamil (adverse effects, therapeutic use)